Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2738019 | 0.86 | KDM4E (0.56) | METAP2KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL19219128 | 0.85 | METAP2 (0.52) | METAP2KDM4ENPC1ALDH1A1KMT2A | |
| SCHEMBL3979169 | 0.82 | METAP2 (1.00) | METAP2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL31376964 | 0.82 | NPC1 (0.71) | METAP2KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL3981460 | 0.81 | METAP2 (0.62) | METAP2 | |
| SCHEMBL3983978 | 0.81 | METAP2 (0.73) | METAP2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL3980105 | 0.80 | METAP2 (0.81) | METAP2KDM4EALDH1A1 | |
| SCHEMBL3988400 | 0.79 | METAP2 (0.74) | METAP2 | |
| SCHEMBL3984413 | 0.79 | METAP2 (1.00) | METAP2KDM4EALDH1A1 | |
| SCHEMBL222213 | 0.79 | METAP2 (0.68) | METAP2KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838900-B1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2838900-B1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10174038-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174038-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2013158776-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | METAP2 1647/4885KDM4E 2069/4885PKM 729/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | METAP2 1647/4885KDM4E 2069/4885PKM 729/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | METAP2 1647/4885KDM4E 2069/4885PKM 729/4885 |
| US-20130273037-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | METAP2 622/4885KDM4E 3612/4885PKM 2342/4885 |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | METAP2 622/4885KDM4E 3612/4885PKM 2342/4885 |
| US-10174038-B2 | Compounds and methods for antiviral treatment | ZC3HAV1, SARS1, MAVS | METAP2 622/4885KDM4E 3612/4885PKM 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.